← Back to Screener
Palvella Therapeutics, Inc. Common Stock (PVLA)
Price$124.18
Favorite Metrics
Price vs S&P 500 (26W)67.86%
Price vs S&P 500 (4W)6.78%
Market Capitalization$1.84B
All Metrics
Book Value / Share (Quarterly)$2.26
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)13.44%
Cash Flow / Share (Quarterly)$-2.02
Price vs S&P 500 (YTD)20.25%
Net Profit Margin (TTM)-39.71%
EPS (TTM)$-3.70
10-Day Avg Trading Volume0.24M
EPS Excl Extra (TTM)$-3.70
Revenue Growth (5Y)8.03%
EPS (Annual)$-7.62
ROI (Annual)-22.80%
Net Profit Margin (5Y Avg)-102.68%
Cash / Share (Quarterly)$4.68
ROA (Last FY)-19.27%
Revenue Growth TTM (YoY)-97.15%
EBITD / Share (TTM)$-3.37
ROE (5Y Avg)-89.63%
Operating Margin (TTM)-47.76%
Cash Flow / Share (Annual)$-2.02
P/B Ratio65.80x
P/B Ratio (Quarterly)44.27x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-73.89x
ROA (TTM)-59.66%
EPS Incl Extra (Annual)$-7.62
Current Ratio (Annual)5.20x
Quick Ratio (Quarterly)5.11x
3-Month Avg Trading Volume0.30M
52-Week Price Return426.31%
Revenue / Employee (TTM)$0
P/S Ratio (Annual)43.01x
Asset Turnover (Annual)1.11x
52-Week High$151.18
Operating Margin (5Y Avg)-106.68%
EPS Excl Extra (Annual)$-7.62
26-Week Price Return71.85%
Quick Ratio (Annual)5.11x
13-Week Price Return28.00%
Total Debt / Equity (Annual)0.63x
Current Ratio (Quarterly)5.20x
Enterprise Value$1,800.944
Revenue / Share Growth (5Y)-2.80%
Asset Turnover (TTM)0.76x
Revenue / Employee (Annual)$3
Pretax Margin (Annual)-57.33%
Cash / Share (Annual)$4.68
3-Month Return Std Dev103.78%
Net Income / Employee (TTM)$-3
ROE (Last FY)-27.15%
Net Interest Coverage (Annual)-9.86x
EPS Basic Excl Extra (Annual)$-7.62
P/FCF (TTM)12274.44x
Receivables Turnover (TTM)1.91x
Total Debt / Equity (Quarterly)0.63x
EPS Incl Extra (TTM)$-3.70
Receivables Turnover (Annual)13.42x
ROI (TTM)-72.09%
P/S Ratio (TTM)44.99x
Pretax Margin (5Y Avg)-102.56%
Revenue / Share (Annual)$38.02
Price vs S&P 500 (52W)396.48%
Year-to-Date Return22.89%
5-Day Price Return-1.21%
EPS Normalized (Annual)$-7.62
ROA (5Y Avg)-36.56%
Net Profit Margin (Annual)-57.33%
Month-to-Date Return3.19%
EBITD / Share (Annual)$-7.62
Operating Margin (Annual)-69.51%
LT Debt / Equity (Annual)0.63x
ROI (5Y Avg)-88.76%
LT Debt / Equity (Quarterly)0.63x
EPS Basic Excl Extra (TTM)$-3.70
P/B Ratio (Annual)44.27x
Pretax Margin (TTM)-39.71%
Book Value / Share (Annual)$2.26
Price vs S&P 500 (13W)27.32%
Beta-0.05x
P/FCF (Annual)38.51x
Revenue / Share (TTM)$0.76
ROE (TTM)-98.14%
52-Week Low$20.20
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.24
4.23
4.23
4.23
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
PVLAPalvella Therapeutics, Inc. Common Stock | 44.99x | -97.15% | — | — | $124.18 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Palvella Therapeutics is a late-stage biopharmaceutical company developing treatments for rare genetic skin diseases that currently lack approved therapies. The company's lead candidate, QTORIN rapamycin gel, is based on its proprietary QTORIN platform and is in clinical development for two rare genetic skin disorders.